Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study Of The Effect Of Rifaximin On B-Cell Dysregulation In Cirrhosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Current or prior chronic Hepatitis C infection as documented by detectable HCV RNA in prior 5 years~* Child-Turcotte-Pugh stage A5-B8. Cirrhosis diagnosis may be based on either histological criteria (an previous liver biopsy showing F4/4 or F5-6/6 fibrosis) or clinical criteria (nodular liver on abdominal imaging, splenomegaly, thrombocytopenia, spider telangiectasias, palmar erythema, ascites, varices).~* Platelet count \< 175,000/ul~* Subject capable of giving informed consent~Exclusion Criteria:~* Active alcohol use \> 20g/d~* Current or planned (within following 6 months) antiviral therapy for hepatitis C~* HIV co-infection~* Diagnosis of overt hepatic encephalopathy~* Current lactulose use~* Exposure to rifaximin, rifampin or rifabutin within 12 months~* History of C. difficile colitis~* History of adverse drug reaction or sensitivity to rifaximin, rifampin or rifabutin or any inactive components of rifaximin~* Pregnancy~* Anemia with hemoglobin \< 10g/dl or hematocrit \< 30%~* Chronic kidney disease with creatinine \> 2.1mg/dl~* Total bilirubin \> 3.0g/dl~* Active non-hepatic medical conditions such as congestive heart failure, chronic lung disease requiring oxygen, coronary artery disease with unstable angina~* Requirement for chronic immunosuppressive therapy such as corticosteroids, cyclophosphamide, azathioprine, TNF-alpha antagonists~* Chronic autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis~* Post-liver transplantation status or anticipated liver transplantation within 6 months.~* Systemic antimicrobial exposure within 30 days of planned Visit 1

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Rifaximin/Placebo (Type: EXPERIMENTAL): Rifaximin 550mg po bid for 12 weeks followed by crossover to matched placebo po bid x 12 weeks
- Placebo/Rifaximin SSD (Type: EXPERIMENTAL): Matched placebo po bid for 12 weeks followed by crossover to Rifaximin 550mg po bid x 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).